KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Convertible Debt: 2011-2025

Historic Convertible Debt for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to $311.4 million.

  • Travere Therapeutics' Convertible Debt rose 0.46% to $311.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $311.4 million, marking a year-over-year increase of 0.46%. This contributed to the annual value of $310.3 million for FY2024, which is 17.75% down from last year.
  • Latest data reveals that Travere Therapeutics reported Convertible Debt of $311.4 million as of Q3 2025, which was up 0.11% from $311.0 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Convertible Debt registered a high of $378.1 million during Q2 2024, and its lowest value of $218.1 million during Q1 2021.
  • Over the past 3 years, Travere Therapeutics' median Convertible Debt value was $376.0 million (recorded in 2023), while the average stood at $346.9 million.
  • In the last 5 years, Travere Therapeutics' Convertible Debt skyrocketed by 71.65% in 2022 and then decreased by 17.75% in 2025.
  • Travere Therapeutics' Convertible Debt (Quarterly) stood at $226.6 million in 2021, then spiked by 65.74% to $375.5 million in 2022, then rose by 0.46% to $377.3 million in 2023, then dropped by 17.75% to $310.3 million in 2024, then rose by 0.46% to $311.4 million in 2025.
  • Its Convertible Debt was $311.4 million in Q3 2025, compared to $311.0 million in Q2 2025 and $310.7 million in Q1 2025.